Nicholas Opalich’s Post

As we navigate the complexities of the pharmaceutical industry, recent insights from The New York Times article “How PBMs Are Driving Up Prescription Drug Costs” highlight a critical issue affecting both pharmacies and patients. Pharmacy Benefit Managers (PBMs) play a significant role in determining the price of prescription drugs, and their practices are increasingly driving up costs. For Curtis Pharmacy, this has direct implications. The rising costs imposed by PBMs can limit our ability to provide affordable medications to our community. It’s crucial for us to advocate for greater transparency and fair practices within the industry to ensure that we can continue to offer quality healthcare without undue financial burdens on our customers. At Curtis Pharmacy, we remain committed to supporting our patients and will continue to fight for a system that prioritizes their health and well-being over profit margins. #Pharmacy #Healthcare #PBMs #DrugCosts #CurtisPharmacy For further reading on how PBMs impact prescription drug costs, check out the full article in The New York Times.

As the U.S. health care system continues to grapple with access and affordability challenges, technological advances like telehealth and digital medicine have the potential to fill some of the gaps—and not just for primary care. Pharmaceutical companies like Eli Lilly and Pfizer are starting to take advantage of these tools to offer consumers direct-to-patient (DTP) options for purchasing prescription drugs. These DTP models have the potential to transform how patients access and afford their medications, offering convenience and efficiency through services like virtual providers and mail-order prescriptions. DTP models offer benefits to manufacturers as well—such as cost savings and the opportunity to interact more directly with patients. However, these new DTP services are not a silver bullet and could also present several challenges if not implemented carefully. Read more about the trend of DTP pharmaceutical models and other market access topics with NAVLIN Daily: https://lnkd.in/dNemWqR8 #Pharma #LillyDirect #PfizerForAll #DTP #telemedicine #pharmacy #access #marketaccess #NAVLIN #EVERSANA #NAVLINDaily

Excited to share our latest project leveraging data analytics to forecast trends in medication prescriptions and adherence! 📊💊 We aimed to anticipate shifts in medication usage, helping healthcare providers and pharmaceutical companies adapt effectively. Here's a snapshot: 🎯 **Objective**: Predicting medication prescription trends and adherence levels, identifying potential increases and decreases. 📊 **Data Sets**: - Medicaid & CHIP Open Data State Drug Utilization via Data.Medicaid.Gov - Drug Reviews via Kaggle.com - Prescription Drug Use in HRRs and HSAs via Kaggle.com 🔍 **Analysis**: - **Linear Regression**: Projecting prescription volumes for each drug in 2030. - **Sentiment Analysis**: Assessing positive and negative responses to drugs to gauge adherence likelihood. Our findings offer actionable insights into future medication trends, empowering stakeholders to make informed decisions in healthcare delivery and pharmaceutical strategy. Exciting times ahead for precision healthcare! 🚀 #DataAnalytics #HealthcareTrends #PredictiveAnalytics

It was great talking about the disruptive potential of DTP for pharma with Raechel Pusateri from NAVLIN by EVERSANA. The paradigm is about to flip with more power to patients and a streamlined commercial model resulting in decreased time to treatment, lower costs and improved outcomes. #pharma #digitaldisruption

Is your pharmaceutical business wasting time managing regular repeat orders? ⅔  Repeats prescriptions account for two-thirds of England’s primary care prescriptions. That’s nearly 80% of all NHS primary care medicine costs. (NHS England) 🪁  Whether you’re a healthcare provider or pharmaceutical manufacturer or distributor Cloudfy streamlines and simplifies regular repeat ordering. 🗓️  With Cloudfy’s subscription ordering feature it’s easy to set up and control, all from an easy to use dashboard. 📦  Integration with warehouse management improves stock control, minimizes waste and improves service to patients. Find out how an NHS partnership with a pharmaceutical giant streamlined and simplified delivering life-saving sensors for diabetes patients. https://lnkd.in/gyBw6VcM #b2b #ecommerce #warehousemanagement #integration #customersevice #pharmaceuticals #nhs

Enhancing Patient Outcomes: The Role of Long-Term Care Facilities for Pharma Manufacturers. There are significant opportunities for pharmaceutical companies, particularly those offering high-quality, branded medications. Many patients in long-term care are dual-eligible for Medicare and Medicaid, so they don’t pay out-of-pocket for medications. This often leads to a preference for branded drugs over generics. Stay ahead with cutting-edge insights from Life Sciences by PointClickCare —follow us on LinkedIn. #Pharmaceuticals #LongTermCare #Healthcare #MedicareMedicaid

All 10 Pharma Companies Respond to Medicare Pricing Negotiations Offers, Progressing Under Inflation Reduction Act The US Department of Health and Human Services (HHS) has announced that all ten pharmaceutical manufacturers involved in Medicare pricing negotiations have made counteroffers. These negotiations are part of efforts to lower drug prices in the United States under the Inflation Reduction Act. The selected drugs include treatments for diabetes, heart failure, cancer, and other conditions. The negotiations aim to ensure access to necessary medications and reduce healthcare costs. Updated prices will be announced by September 2024, with implementation planned for 2026. The Biden administration is focused on making prescription drugs more affordable for all Americans. For more details please click the link! https://lnkd.in/dzw6CtMb #marketaccess #reimbursement #pricing #hta #heor #healtheconomics #medicaldevices #pharmaceutical

Rick Fry, VP Strategic Development, is one of our resident experts at GoodRx at understanding and articulating the complexities of the U.S. healthcare system, as well as helping the team create access and affordability solutions that benefit consumers, healthcare professionals (HCPs),and pharmaceutical manufacturers. In today’s Drug Channels’ guest post, Rick asserts that more financial demands on U.S. consumers for their healthcare are, in part, the result of increases in utilization management and patient cost-sharing for prescription drugs, with more consumers opting to pay cash. GoodRx’s integrated platform model offers pharmaceutical companies a more seamless and frictionless way to deliver value to consumers—at scale—while they care for themselves and their loved ones. Click the link to read the full article at Drug Channels: https://lnkd.in/ehUDbD6x

Pharmacy’s Role in Treating Rare Disease: Connecting Patients, Providers, Payers, and Pharma: Pharmacy's position at the intersection of the care team gives it a unique ability to connect providers, payers, and pharmaceutical manufacturers, and support patients to maximize their health outcomes. #finance #pharmacy #lifesciences

Our latest Healthcare Payments Data visualization sheds light on various aspects of the cost of pharmaceuticals in the commercial market in California in 2021. For example, the 25 costliest drugs account for just 3.2 percent of all prescriptions in the commercial market, but account for nearly 30 percent of total costs at more than $3.9 billion in 2021. Click the link below to see the entire data product: https://bit.ly/4c7us3h